EyePoint Inc. Common Stock (EYPT)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business and the numbers. EyePoint is a biotechnology company developing retinal disease therapies, with DURAVYU as its lead candidate and a proprietary Durasert E sustained-delivery technology. That is a promising scientific story, but the financial statements show no durable moat yet. In fiscal 2025, the year ended 2025-12-31, revenue was $31.4 million, down from $43.3 million in fiscal 2024 and $46.0 million in fiscal 2023. Net loss widened to $232.0 million, or $3.17 per diluted share, in fiscal 2025. The latest quarter, fiscal Q2 2026 ended 2026-06-30, had revenue of only $507,000 and a net loss of $94.5 million, or $1.09 per diluted share. Trailing free cash flow was negative $271.3 million, and the FairStock-calculated FCF yield was negative 102.5%. Those are not the marks of a self-funding business. The balance sheet has low debt—D/E of 0.13—but Altman Z-score of -5.94 and Piotroski F-score of 2/9 suggest distress. At $3.07 on 2026-10-13, market cap is $264.7 million. P/B is 1.57 and P/E is negative 0.82, both FairStock calculations, but with no profits, the P/E is meaningless and book value may not protect shareholders if losses continue. Revenue growth is negative 90.49% and profit growth negative 58.97%. The stock is near its 52-week low of $3.05, so the market has already repriced it sharply. Graham would demand a margin of safety; here the value depends almost entirely on clinical success, not on present earnings. I see a speculative pipeline, not a proven compounding machine.

In plain English: EyePoint is a small healthcare company working on treatments for serious eye diseases, especially a long-acting drug-delivery treatment. The business looks weak right now: revenue is tiny and falling, and it is losing large amounts of money. The stock price has dropped close to its 52-week low, but because there are no profits and cash is being used up, it does not look like a clear bargain based on its current numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer